| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 628 | 537 | 285 | 235 | 144 | 77 | 62 | 436 | 394 | 66 |
| Total Expenses - EUR | 2.816 | 620 | 787 | 303 | 4.093 | 2.433 | 1.742 | 2.916 | 2.377 | 1.404 |
| Gross Profit/Loss - EUR | -2.188 | -83 | -502 | -68 | -3.950 | -2.356 | -1.680 | -2.480 | -1.984 | -1.338 |
| Net Profit/Loss - EUR | -2.188 | -83 | -502 | -68 | -3.950 | -2.356 | -1.680 | -2.480 | -1.984 | -1.338 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Aplasimob S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 59.782 | 59.172 | 58.171 | 57.103 | 55.997 | 54.936 | 53.718 | 53.884 | 53.721 | 53.421 |
| Current Assets | 10.632 | 10.508 | 10.314 | 10.074 | 9.801 | 9.516 | 9.268 | 9.297 | 9.269 | 10.180 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 10.314 | 10.209 | 10.037 | 9.852 | 9.662 | 9.478 | 9.268 | 9.297 | 9.269 | 10.180 |
| Cash | 318 | 299 | 278 | 221 | 139 | 37 | 0 | 0 | 0 | 0 |
| Shareholders Funds | -2.463 | -2.521 | -2.980 | -2.993 | -6.885 | -9.110 | -10.588 | -13.101 | -15.045 | -16.299 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 72.877 | 72.201 | 71.465 | 70.170 | 72.683 | 73.561 | 73.574 | 76.283 | 78.035 | 79.900 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "111 - 111" | |||||||||
| CAEN Financial Year |
111
|
|||||||||
Comments - Aplasimob S.r.l.